Therapeutic potential of non-steroidal anti-inflammatory drugs (NSAIDs) targeting COX-2, 5LO pathways, PGE2 receptor (EP receptor) antagonists blocking LTB4 secretion has been tested in the vascular malignancy KS and B cell lymphoproliferative disease PEL (George Paul et al., 2010; Paul et al., 2011; Paul et al., 2013; Sharma-Walia et al., 2014). Here, PTGS2 is linked to primary effusion lymphoma.